Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lung Neoplasms × Clindamycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Tract Infections 1 Urinary Bladder Neoplasms 1 Surgical Wound Infection 1 Skin Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Inflammation 1 Infections 1 Head and Neck Neoplasms 1 Exanthema 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Carboplatin 177 Radiotherapy 137 Cisplatin 110 Pemetrexed 102 Docetaxel 93 Paclitaxel 92 Gemcitabine 77 Erlotinib Hydrochloride 73 Magnetic Resonance Spectroscopy 69 Radiosurgery 66 Bevacizumab 65 pembrolizumab 63 Etoposide 60 Blood Specimen Collection 60 durvalumab 52 Surveys and Questionnaires 46 Nivolumab 46 Specimen Handling 45 Drug Therapy 40 Standard of Care 34 osimertinib 32 atezolizumab 32 Radiation 32 Surgical Procedures, Operative 30 Topotecan 29 Irinotecan 29 Gefitinib 29 Biopsy 28 Vinorelbine 27 Educational Status 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡